Linked Life Data

9834111

Source:http://linkedlifedata.com/resource/pubmed/id/9834111

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1998-12-21
pubmed:abstractText
Dendritic cells (DC) are regarded as attractive candidates for cancer immunotherapy. Our aim is to improve the therapeutic efficacy of DC-based tumor vaccine by augmenting DC preferential chemotaxis on T cells. Mouse bone marrow-derived DC were transduced with lymphotactin (Lptn) gene by adenovirus vector. The supernatants from Lptn gene-modified DC (Lptn-DC) were capable of attracting CD4+ and CD8+ T cells in a chemotaxis assay, whereas their mock control could not. Lptn expression of Lptn-DC was further confirmed by RT-PCR. Lptn-DC were pulsed with Mut1 peptide and used for vaccination. Immunization with the low dose (1 x 10(4)) of Mut1 peptide-pulsed DC induced weak CTL activity, whereas the same amounts of Mut1 peptide-pulsed Lptn-DC markedly induced specific CTL against 3LL tumor cells. A single immunization with 1 x 10(4) Mut1 peptide-pulsed Lptn-DC could render mice resistant to a 5 x 10(5) 3LL tumor cell challenge completely, but their counterpart could not. The protective immunity induced by Mut1 peptide-pulsed Lptn-DC depends on both CD4+ T cells and CD8+ T cells rather than NK cells in the induction phase and depends on CD8+ T cells rather than CD4+ T cells and NK cells in the effector phase. Moreover, the involvement of CD28/CTLA4 costimulation pathway and IFN-gamma are also necessary. When 3LL tumor-bearing mice were treated with 1 x 10(4) Mut1 peptide-pulsed Lptn-DC, their pulmonary metastases were significantly reduced, whereas the same low dose of Mut1 peptide-pulsed DC had no obvious therapeutic effects. Our data suggest that Lptn-DC are more potent adjuvants for peptide delivery to induce protective and therapeutic antitumor immunity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
161
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6238-44
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9834111-Adenoviridae, pubmed-meshheading:9834111-Animals, pubmed-meshheading:9834111-Antigens, Neoplasm, pubmed-meshheading:9834111-Bone Marrow Cells, pubmed-meshheading:9834111-Bone Marrow Transplantation, pubmed-meshheading:9834111-Carcinoma, Lewis Lung, pubmed-meshheading:9834111-Cell Line, pubmed-meshheading:9834111-Chemokines, C, pubmed-meshheading:9834111-Cytotoxicity, Immunologic, pubmed-meshheading:9834111-Dendritic Cells, pubmed-meshheading:9834111-Female, pubmed-meshheading:9834111-Genetic Vectors, pubmed-meshheading:9834111-Humans, pubmed-meshheading:9834111-Immunotherapy, Adoptive, pubmed-meshheading:9834111-Injections, Subcutaneous, pubmed-meshheading:9834111-Lymphocyte Depletion, pubmed-meshheading:9834111-Lymphokines, pubmed-meshheading:9834111-Mice, pubmed-meshheading:9834111-Mice, Inbred BALB C, pubmed-meshheading:9834111-Mice, Inbred C57BL, pubmed-meshheading:9834111-Oligopeptides, pubmed-meshheading:9834111-Sialoglycoproteins, pubmed-meshheading:9834111-T-Lymphocytes, Cytotoxic, pubmed-meshheading:9834111-Tumor Cells, Cultured
pubmed:year
1998
pubmed:articleTitle
Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
pubmed:affiliation
Department of Immunology, Second Military Medical University, Shanghai, People's Republic of China. caoxt@public3.sta.net.cn
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't